A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
TO THE EDITOR: Since 2000, several small randomized controlled trials have demonstrated that ketamine has potent and rapid-acting antidepressant effects in patients with treatment-resistant depression (1). Despite a lack of longterm data or Food and Drug Administration indication, many community providers and academic centers have begun offering ketamine treatment to patients with major depressive disorder and with other psychiatric disorders, determining the existing evidence justifies use for some individuals. Thepractice patterns of suchprovidershavenot been studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An overall total of 33,240 (e.g.23,420 zolpidem; 9,283 zopiclone; and 537 zaleplon) misuse/abuse/dependence and withdrawal-related ADRs, corresponding to some 6,246 unique patients, were identified.”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“Out of these three molecules, zolpidem and zopiclone presented with the same dependence risk, but zolpidem was the most frequently associated with withdrawal issues.Zaleplon was the least reported for these ADRs (see Table 1).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders
Sanacora, G., Heimer, H., Hartman, D., Mathew, S. J., Frye, M., Nemeroff, C. B., & Beale, R. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.193 · Cited by 37
Self-citation
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“These concerns are amplified by the rapid increase in the numbers of practitioners and community-based clinics in the United States that have expanded their scope of practice to include ketamine for TRD (16).”
BackgroundSelf-citationKetamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455
Self-citationHashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Ketamine-induced side-effects are suggested to be associated with NMDAR inhibition.(59,102,103,140) (S)-ketamine is metabolized to (S)Fig.”
BackgroundThe role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173
“A rapidly growing number of mental health care providers have begun to offer ketamine as an off-label treatment for mood disorders [40]; however, there is no organized registry that is documenting safety outcomes from the large numbers of patients who are receiving ketamine off-label.”
BackgroundSelf-citationConvergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“Although ketamine is increasingly being used as a treatment [357], there is not a single rapid-acting antidepressant medication that is approved for the treatment of major depression to date.”
BackgroundLong-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
“Fortunately, many providers who offer off-label ketamine also report that they monitor blood pressure in some form on a regular basis [46,47].”
BackgroundSelf-citationAMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
“These data have led to ketamine’s off-label use and the emergence of specialized ketamine clinics and emergency room protocols to treat severely depressed and suicidal individuals (32).”
BackgroundAn update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
“Collectively, it is likely that single or repeated ketamine infusions may be a therapeutic alternative for patients with GAD or SAD.”
BackgroundInfluentialThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
“An additional concern is that the use of multiple ketamine infusions as a treatment for TRD has increased in recent years (Wilkinson et al., 2017).”
BackgroundThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Wilkinson, S. T., Katz, R. B., Toprak, M., Webler, R., Ostroff, R. B., & Sanacora, G. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11731 · Cited by 91
“Biological psychiatry 2012 6 01;71(11): 939–946.”
Self-citationWilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.004 · Cited by 95
Self-citationKetamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
“In practice, specialized ketamine clinics may not uniformly uphold this standard, which raises an ethical concern in light of relatively high out-of-pocket expenses to patients [6].”
BackgroundSelf-citationThe emergence of ketamine as a novel treatment for posttraumatic stress disorder
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.05.004 · Cited by 65
Tian, Z., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.07.003 · Cited by 62
“Although there remain concerns about the safety of repeated (R,S)-ketamine infusions, (R,S)-ketamine has been used widely as off-label treatment for mood disorders (Sanacora et al., 2017; Wilkinson et al., 2017; Zhang et al., 2016).”
Feeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 65
Mathew, S. J., Wilkinson, S. T., Altinay, M., Asghar-Ali, A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.12.009 · Cited by 54
Self-citationKetamine as a Treatment for Anorexia Nervosa: A Narrative Review
Keeler, J. L., Treasure, J. L., Juruena, M. F., Kan, C., & Himmerich, H. (2021) · Nutrients · doi:10.3390/nu13114158 · Cited by 61
“For example, it has been found that a third of patients with treatment-resistant depression achieve remission [10], with higher rates of remission associated with repeated administrations.”
BackgroundThe effects of ketamine on suicidality across various formulations and study settings
Dadiomov, D., & Lee, K. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.01.048 · Cited by 53
“In addition, long-term effects of ketamine are not well described in the literature despite an increasing number of providers of various formulations of ketamine.(44) Finally, the majority of these”
BackgroundLangmia, I. M., Just, K. S., Yamoune, S., Müller, J. P., & Stingl, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15467 · Cited by 47
“Off-label use of ketamine has also been reported by private practitioners in some countries.(4,5)”
BackgroundJha, M. K., Wilkinson, S. T., Krishnan, K., Collins, K. A., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M. I., Aloysi, A. S., Asghar‐Ali, A. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17786 · Cited by 45
Self-citationKetamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 45
“27,28 An open-label study examining the effect of repeated ketamine infusions for the treatment of patients with TRD and comorbid posttraumatic stress disorder (PTSD) in a sample of veterans had a remission rate of 80% for PTSD, and a response rate of 93.3% for TRD. PTSD responders had a median…”
InfluentialConsiderations on the Off-label Use of Ketamine as a Treatment for Mood Disorders
Wilkinson, S. T., & Sanacora, G. (2017) · JAMA · doi:10.1001/jama.2017.10697 · Cited by 38
Self-citationStudies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
“The extent of off-label, non-evidence based use is of concern with ketamine since it has the potential for behavioral toxicity and lacks long-term safety data (Wilkinson and Sanacora, 2017; Wilkinson et al., 2017).”
The Rapidly Shifting Ketamine Landscape in the US
Wilkinson, S. T., Palamar, J. J., & Sanacora, G. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4945 · Cited by 43
Self-citationSakurai, H., Yonezawa, K., Tani, H., Mimura, M., Bauer, M., & Uchida, H. (2022) · Pharmacopsychiatry · doi:10.1055/a-1714-9097 · Cited by 42
“For example, multiple studies have demonstrated the effectiveness of ketamine, an N-methyl-Daspartate receptor (NMDAR) antagonist, and (s)-ketamine, an Senantiomer of ketamine, for treatment-resistant depression (TRD) and suicidal ideation [11, 12].”
BackgroundAn Update on Community Ketamine Practices
O’Brien, B., Wilkinson, S. T., & Mathew, S. J. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21111086 · Cited by 41
Self-citationMaffioletti, E., Minelli, A., Tardito, D., & Gennarelli, M. (2020) · Genes · doi:10.3390/genes11091089 · Cited by 39
Salloum, N. C., Fava, M., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.017 · Cited by 34
“fewer clinic visits) and reducing its cost (clinicians currently employ two to three infusions per week (Wilkinson et al., 2017)).”
BackgroundSelf-citationAcevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D. K., Kraus, C., Kadriu, B., Park, L., & Zarate, C. A. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.06.012 · Cited by 36
Morris, P. J., Burke, R. D., Sharma, A. K., Lynch, D. C., Lemke-Boutcher, L. E., Mathew, S., Elayan, I., Rao, D. B., Gould, T. D., Zarate, C. A., et al. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.106993 · Cited by 36
“Ketamine, an N -methyl- D -aspartate receptor (NMDAR) antagonist, has emerged as an effective therapy for treatment-resistant depression (Zarate Jr et al., 2006; Newport et al., 2015; Wilkinson et al., 2017).”
Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine
Wilkinson, S. T., Howard, D. H., & Busch, S. H. (2019) · JAMA · doi:10.1001/jama.2019.10728 · Cited by 35
Self-citationLarrea, A., Sánchez-Sánchez, L., Díez-Martín, E., Elexpe, A., Torrecilla, M., Astigarraga, E., & Barreda‐Gómez, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061727 · Cited by 34
Zhang, K., Toki, H., Fujita, Y., Ma, M., Chang, L., Qu, Y., Harada, S., Nemoto, T., Mizuno‐Yasuhira, A., Yamaguchi, J., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5017-2 · Cited by 33
Safety of Repeated Administration of Parenteral Ketamine for Depression
Feifel, D., Dadiomov, D., & C. Lee, K. (2020) · Pharmaceuticals · doi:10.3390/ph13070151 · Cited by 31
“Despite this dearth of evidence concerning the long-term use of ketamine for depression, a growing number of providers have begun to use ketamine to treat refractory depression, often in clinics that focus on offering this treatment [15].”
BackgroundResultCotter, S., Wong, J., Gada, N., Gill, R., Jones, S. C., Chai, G. P., Foster, D. K., Avigan, M., & Mundkur, M. L. (2021) · Drug Safety · doi:10.1007/s40264-021-01120-9 · Cited by 31
Giakoumatos, C. I., & Osser, D. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27
Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. K., & Swainson, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1283733 · Cited by 29
“More treatment-resistant patients have been reported as less likely to fully remit, but not less likely to respond to treatment (17).”
BackgroundKeeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Alario, A. A., & Niciu, M. J. (2021) · Chronic Stress · doi:10.1177/24705470211014210 · Cited by 26
Baudot, J., Soeiro, T., Tambon, M., Navarro, N., Veyrac, G., Mezaache, S., & Micallef, J. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12745 · Cited by 26
“Infusions of subanesthetics doses of ketamine have a long-term history of off-label use in treatment-resistant depression [21].”
BackgroundAgboola, F., Atlas, S. J., Touchette, D. R., Fazioli, K., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.16 · Cited by 24
“Although concerns remain about its long-term safety and potential for abuse or diversion, the off-label use of ketamine for the treatment of patients with TRD has been expanding in the United States.(8) While ketamine is a racemic”
Trends and characteristics in ketamine use among US adults with and without depression, 2015–2022
Yang, K. H., Kepner, W. E., Cleland, C. M., & Palamar, J. J. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.108 · Cited by 24
Katz, R., Toprak, M., Wilkinson, S. T., Sanacora, G., & Ostroff, R. B. (2018) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.05.007 · Cited by 25
Self-citationJilka, S., Murray, C., Wieczorek, A., Griffiths, H., Wykes, T., & McShane, R. H. (2019) · BJPsych Open · doi:10.1192/bjo.2019.52 · Cited by 22
Levin, A. W., Nagib, P. B., Deiparine, S., Gao, T. Z., Mitchell, J. J., & Davis, A. K. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103816 · Cited by 23
Ketamine: A Review for Clinicians
Sanacora, G., & Katz, R. R. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180012 · Cited by 22
“tonically inhibits release of presynaptic glutamate (2), resulting in minimal activation”
BackgroundResultInfluentialSelf-citationComing Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Li, S. W., Kumpf, K. T., Urrutia, J., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250276 · Cited by 19
Self-citationAgnorelli, C., Cinti, A., Barillà, G., Lomi, F., Scoccia, A., Benelli, A., Neri, F., Smeralda, C. L., Cuomo, A., Santarnecchi, E., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02889-2 · Cited by 17
Xiong, Z., Zhang, K., Ishima, T., Ren, Q., Ma, M., Pu, Y., Chang, L., Chen, J., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.010 · Cited by 17
“, psychotomimetic effects and dissociative effects) of (R,S)-ketamine are not resolved (Singh et al., 2017; Wilkinson et al., 2017).”
Past-Year Ketamine Use: Evidence from a United States Population, 2015-2019
Yockey, R. A. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2058896 · Cited by 16
“, depression) and substance use dependence (Jones et al. 2018; Wilkinson et al. 2017).”
BackgroundMapping consent practices for outpatient psychiatric use of ketamine
Mathai, D. S., Lee, S. M., Mora, V., O’Donnell, K. C., Garcia‐Romeu, A., & Storch, E. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.036 · Cited by 16
“In the context of increasing numbers of community-based practitioners offering ketamine as an indiscriminate psychiatric treatment (Wilkinson et al., 2017), several groups have proposed best practice guidelines derived from existing evidence (McIntyre et al., 2021; Sanacora et al., 2017; Singh et…”
Schuman, H. D. M., Savard, C., Mina, R., Barkova, S., Conradi, H. S. W., Deleemans, J. M., & Carlson, L. E. (2025) · Current Oncology · doi:10.3390/curroncol32070380 · Cited by 14
“However, it lacks formal regulatory approval for use in cancer populations and is increasingly being applied more broadly across clinical contexts [12,67].”
Advanced training in interventional psychiatry
Nikayin, S., Taylor, J. J., & Ostroff, R. B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120093 · Cited by 13
O’Brien, B., Green, C. E., Jurdi, R. K. A., Chang, L. C., Lijffijt, M., Iqbal, S., Iqbal, T., Swann, A. C., & Mathew, S. J. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100432 · Cited by 13
Long-term follow-up of participants in ketamine clinical trials for mood disorders
Hurst, K. T., Vogeley, A., GREENSTEIN, D. K., Durland, L., Makel, S., Wang, P. R., Yavi, M., Zarate, C. A., & Ballard, E. D. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.062 · Cited by 12
A novel framework for ketamine-assisted couple therapy
Khalifian, C. E., Rashkovsky, K. T., Mitchell, E., Bismark, A. W., Wagner, A. C., & Knopp, K. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1376646 · Cited by 12
Thornton, N. L. R., Kawalsky, J., Milton, A. C., Klinner, C., Schokman, A., Stratton, E., Loo, C. K. A., & Glozier, N. (2023) · BJPsych Open · doi:10.1192/bjo.2023.75 · Cited by 11
Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10
“Ketamine clinics—where intravenous ketamine is administered by clinical providers off-label—have also emerged in community settings (Wilkinson et al., 2017).”
BackgroundShanok, N. A., Muzac, S., Brown, L., Barrera, M., & Rodriguez, R. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06573-1 · Cited by 10
“A meta-analysis from Wilkinson et al. (2017) found that single administrations of ketamine generated rapid reductions in suicidal ideation (within a single day) on an array of clinician-administered and self-reported scales with moderate to large effect sizes (Cohen’s d = 0.48 – 0.85).”
InfluentialPatterns and Predictors of Off-Label Drug Prescribing in Psychiatric Practice: A Qualitative Study
Shakeel, S., Nesar, S., Rehman, H., Jamil, K., Mallick, I. A., Mustafa, M. S., Anwar, M., & Jamshed, S. Q. (2021) · Pharmacy · doi:10.3390/pharmacy9040203 · Cited by 10
Aslam, A., Shinozuka, K., Muir, O. S., & Tabaac, B. J. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001951 · Cited by 10
“At the time that Wilkinson et al 7 was published, ketamine treatment for TRD was relatively new.”
InfluentialCombining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial
Delgado, A. D., Murrough, J. W., Sloan, D. M., Charney, D. S., Pietrzak, R. H., Schiller, D., Yehuda, R., Costi, S., Jha, M. K., Feder, A., et al. (2025) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15622 · Cited by 9
Can mind-altering prescription medicines be safe? Lessons from ketamine and esketamine
Dart, R. C. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2380773 · Cited by 9
Niciu, M. J., Meisner, R. C., Carr, B. R., Farooqui, A. A., Feifel, D., Kaplin, A. I., Kendrick, E., Kim, P. M., Schneck, C. D., Voort, J. L. V., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.008 · Cited by 8
Blood pressure changes during ketamine infusion for the treatment of depression
Ansari, M., Pittman, B. P., Tylee, D. S., Ostroff, R. B., Wilkinson, S. T., & Nikayin, S. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.07.001 · Cited by 8
Self-citationBrendle, M., Ragnhildstveit, A., Slayton, M. A., Smart, L., Cunningham, S. R., Zimmerman, M. H., Seli, P., Gaffrey, M. S., Averill, L. A., & Robison, R. J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00234 · Cited by 8
Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
Dadiomov, D. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.20 · Cited by 7
“Many of these “new” providers of ketamine were not formally trained to treat psychiatric disorders (many were trained in anesthesia or emergency medicine).(9) Some practices may have used different formulations or doses of ketamine than had been previously reported to be efficacious.”
BackgroundLevinstein, M. R., Schoenborn, I., Manza, P., Schatzberg, A. F., Zarate, C. A., Bonaventura, J., & Michaelides, M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.021 · Cited by 6
Psychopharmacology and Experimental Therapeutics for Bipolar Depression
Jha, M. K., & Murrough, J. W. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190009 · Cited by 6
Banov, M. D., Landrum, R. E., Moore, M. B., & Szabo, S. T. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001456 · Cited by 6
“An increasing number of health care providers are offering intravenous (IV) ketamine off-label for acutely suicidal patients and for thosewho have not responded to approved antidepressant therapies.(13) There are randomized, controlled trials using IV ketamine to treat TRD and acutely suicidal patients, but these arem…”
BackgroundBonaventura, J., Lam, S., Carlton, M. L., Boehm, M. A., Gomez, J. L., Solís, Ó., Sánchez‐Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01480-3 · Cited by 6
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Self-citationKetamine: A Promising Rapid-Acting Antidepressant
Wilkinson, S. T., Ostroff, R. B., Katz, R. B., & Krystal, J. H. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_16 · Cited by 5
Self-citationJha, M. K., & Trivedi, M. H. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180013 · Cited by 5
Trend and geo-availability of somatic therapies for treatment resistant depression in the US
Basiru, T., Onyeaka, H., Oladunjoye, A. F., Acholonu, C., Egbeocha, S., Ogala, F., Enemuo, S., Okoronkwo, O. U., Annor, E., Holmes, K., et al. (2024) · Psychiatry Research Communications · doi:10.1016/j.psycom.2024.100157 · Cited by 4
Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review
Ng, S. H., Lee, Y. Z., Hong, M. Y., Kow, A. S. F., d’Arqom, A., Tham, C. L., Ho, Y., & Lee, M. T. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328362434250224105609 · Cited by 4
López‐Díaz, Á., de Lope, L. R., & Vega, D. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.036 · Cited by 4
Development of Ketamine Administration as a Treatment for Chronic PTSD
Collins, A. B., Rutter, S., & Feder, A. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200109-01 · Cited by 4
New Billing Codes Offer Opportunity to Investigate Psychedelic Treatment
Ostrovsky, A., & Barnett, B. S. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0071 · Cited by 4
Hepatobiliary Complications Associated With Ketamine Use: Clinical Insights and Future Directions
Waheed, H. W., Ashraf, M. R., Sajjad, T., Jehangir, H., Baig, I., Zulaid, A., Nasir, A. R., & Dad, A. (2025) · Cureus · doi:10.7759/cureus.84974 · Cited by 3
Lam, H., Lo, T. L., Yeung, K. L. A., Cheung, N., Cheung, E. F. C., Fu, C. K., Lam, C., Lee, Y. K., Pao, R. S., Sung, W. K., et al. (2025) · Asia-Pacific Psychiatry · doi:10.1111/appy.70010 · Cited by 3
“The use of IV ketamine has been shown to be effective against suicidality and is used elsewhere in the world (Bahji et al. 2021; Wilkinson et al. 2017; Wilkinson and Sanacora 2017; Xiong et al. 2020), but is not licensed in Hong Kong.”
Hallucinogen use in the United States, 2021–2023: Diverging trends and subgroup patterns
Chen, J.-J., Berg, C. J., & Yang, Y. T. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100410 · Cited by 3
“As ketamine is prescribed for depression and other indications, expanded availability may increase opportunities for diversion and nonmedical use, underscoring the need for clear clinical guidance, patient education, and harm-reduction messaging (Wilkinson et al., 2017).”
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Lie, P. E., Lie, T., Nguyen, M., & Lie, D. Y. C. (2026) · Healthcare · doi:10.3390/healthcare14050634 · Cited by 3
“Therapeutic dose involves 0.5 mg/kg, usually administered via IV injection, which is a subanesthetic dose that does not risk the higher risks of drug pharmacology found in recreational settings [33].”
InfluentialInibidores da monoaminoxidase e cetamina intravenosa: uma associação segura?
dos Santos, J. M. L., Couto, H. L. D. O., & Monteiro, D. C. (2022) · Debates em Psiquiatria · doi:10.25118/2763-9037.2022.v12.219 · Cited by 4
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians
Elliott, S. I., Katz, R. B., Ostroff, R. B., Ansari, M., Holmes, S. E., & Sanacora, G. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240040 · Cited by 2
Self-citationWilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
Self-citationSyed, O. A., Sobolenko, V., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., & Giacobbe, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01296-7 · Cited by 2
“This finding is especially relevant for repeated dosing regimens in real-world clinic settings where treatments are typically paid for out-of-pocket by the patients [188, 189].”
Determination of the enantiomeric makeup of ketamine in street drug samples
Shuda, S. A., & Sisco, E. (2026) · Forensic Chemistry · doi:10.1016/j.forc.2026.100787 · Cited by 2
Intravenous ketamine infusions in patients with depression and Epilepsy: Case series
Wiglusz, M. S., Chmielewska, Z., & Cubała, W. J. (2024) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2024.110908 · Cited by 2
Ketamine Treatment for Mood Disorders
Klise, A., Lerner, B. S., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180315-01 · Cited by 2
Self-citationKheirabadi, G., & Golkar, S. (2023) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs-137879 · Cited by 2
Metadata
- Authors
- Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G.
- Affiliations
- Yale University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2017-07-01
- Volume
- 174
- Issue
- 7
- Pages
- 695-696
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC5549850
- OpenAlex
- W2731109846
- Cited by
- 125
- References
- 5
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 15 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 10 · 2019: 18 · 2018: 18 · 2017: 3
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK6 RX002458)
- National Institutes of Health (UL1TR001863)
- National Institute of Mental Health (T32MH062994, L30 MH111000)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- ketamine, off-label drug use, mental illness, treatment-resistant depression
- MeSH terms
- Antidepressive Agents, Bipolar Disorder, Depressive Disorder, Humans, Ketamine, Stress Disorders, Post-Traumatic, Treatment Outcome, Antimanic Agents, Health Care Surveys, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.